When wealthy nations hoarded vaccine supplies during the COVID-19 pandemic, many African countries waited months for access to doses that could have saved lives—a stark reminder that a continent of 1.4 billion people had almost no say in determining its own health destiny. For decades, Africa occupied the weakest link in the global vaccine supply chain, importing the vast majority of its vaccines, pharmaceuticals, and essential medical supplies with little bargaining power or reliable recourse when crises struck. The 2014–2016 Ebola outbreak in West Africa had already signalled the danger; COVID-19 proved it catastrophically real.
Now the continent is embarking on one of its most ambitious health transformations. Africa has set a goal of producing 60 percent of its vaccine requirements locally by 2040—a seismic shift from the roughly 1 percent it produced before the pandemic. This is far more than an industrial target. It represents a deliberate strategy to achieve health sovereignty, scientific self-reliance, economic development, and genuine pandemic preparedness for the future.
The transformation is already taking shape through regional manufacturing hubs. South Africa has emerged as a scientific leader through Afrigen Biologics and Vaccines, which has demonstrated that African scientists can develop advanced mRNA vaccine technologies—the same cutting-edge platform used globally during COVID-19. Rwanda is rapidly positioning itself as an emerging biotechnology hub through partnerships with international pharmaceutical companies, investing in modern facilities and workforce development. Senegal is expanding its production capabilities to serve West African markets, reflecting a critical reality: no single country can supply the entire continent. Multiple regional manufacturing centres are essential for resilience and equitable access.
But manufacturing facilities alone are not enough. Africa's strategy increasingly recognizes that vaccine security requires an entire ecosystem—research institutions, clinical trial networks, regulatory agencies, supply chains, skilled workforces, financing mechanisms, and procurement systems. This systems-based approach distinguishes the current effort from earlier attempts at pharmaceutical production. The African Vaccine Manufacturing Accelerator exemplifies this broader vision, aiming to mobilise up to one billion dollars to reduce investment risks, attract private-sector participation, and support long-term market stability.
The African Continental Free Trade Area is playing a critical supporting role by expanding market access, reducing trade barriers, and facilitating the movement of medical products across borders. These developments reflect a growing recognition that health security and economic security are deeply interconnected—that a continent investing in its own capacity to produce life-saving medicines is also investing in its own future.
The stakes have never been clearer. As new disease threats continue to emerge, including recurring Ebola outbreaks and concerns about future zoonotic diseases, building a strong vaccine manufacturing ecosystem has become central to Africa's long-term resilience. The pandemic taught a harsh lesson about the cost of dependence. Africa is determined not to learn it again.